HL7 FHIR® Pharmaceutical Quality

Drug Product Stability Study

Stelbat Tablets, 20mg — ICH CTD Section 3.2.P.8

Study ID: ABC1234
Status: Final
Duration: 18 months
Start: 2020-12

Storage Conditions

Long-Term 25°C / 60% RH
Accelerated 40°C / 75% RH

Study Conclusion

The shelf life can be 18 months

Test Scope

Description
Degradation
Water Content
Microbiological
Uniformity

Study Protocol Schedule

Condition Initial 3 mo 6 mo 9 mo 12 mo 18 mo 24 mo
Long-Term
25°C/60% RH
XYZ X X X XY XY XY
Accelerated
40°C/75% RH
XYZ X X

X = Description + Degradation + Water Content   |   Y = Microbiological Quality   |   Z = Uniformity of Dosage Units

Degradation Trends — Long-Term 25°C/60% RH

Impurity 1
Impurity 2
Impurity 3
Total
2.5% 2.0% 1.5% 1.0% 0% Initial 18 months Total Limit (2.3%) Imp 1 Limit (0.8%) 0.50% 0.22% 1.20%

Stability Results

Test Acceptance Criteria Initial (B1) Initial (B2) Initial (B3) 18m (B1) 18m (B2) 18m (B3)
Description Orange film-coated... Complies Complies Complies Complies Complies Complies
Impurity 1 ≤ 0.8% w/w 0.101 0.111 0.121 0.501 0.511 0.521
Impurity 2 ≤ 0.4% w/w 0.201 0.201 0.201 0.221 0.221 0.221
Total Degradation ≤ 2.3% w/w 0.801 0.811 0.821 1.201 1.211 1.221
Water Content ≤ 0.2% w/w 0.150 0.155 0.158 0.190 0.192 0.195
Test Acceptance Criteria Initial (B1) Initial (B2) Initial (B3) 6m (B1) 6m (B2) 6m (B3)
Description Orange film-coated... Complies Complies Complies Complies Complies Complies
Impurity 1 ≤ 0.8% w/w 0.101 0.111 0.121 0.710 0.715 0.720
Total Degradation ≤ 2.3% w/w 0.801 0.811 0.821 1.550 1.560 1.580
Water Content ≤ 0.2% w/w 0.150 0.155 0.158 0.195 0.196 0.198

FHIR Resource Explorer

▼ 📄 DiagnosticReport 1 resource
▼ 📋 PlanDefinition 1 definition
▶ ⚙️ ActivityDefinition 10 activities
📄 ActivityDefinition/610ca25c-6126-6117-8d4d-9458ccc33ce2
📄 ActivityDefinition/d99c1b63-2d32-4887-8157-525cc8ae4732
📄 ActivityDefinition/38704856-0acf-95f0-000f-a933b6862fa0
📄 ActivityDefinition/4bfe1ee8-91ed-5c1b-3045-c749bb9d1d90
📄 ActivityDefinition/f19a68b0-4ba1-7288-635e-12783035935b
📄 ActivityDefinition/ce2df6ab-5087-435c-35cb-a84572e756a2
📄 ActivityDefinition/cf2df6ab-5087-435c-35cb-a84572e756a2
📄 ActivityDefinition/096e3f32-798e-6792-76ad-4ea783521c50
📄 ActivityDefinition/77f86b13-8193-3df7-8362-ab5e79ba541d
📄 ActivityDefinition/6b96124b-1a44-0b6b-6783-d6c49360230b
▶ 📐 ObservationDefinition 11 definitions
📄 ObservationDefinition/d1d252cf-9d58-43a0-85f6-56a7f7f92774
📄 ObservationDefinition/1178fc31-0cfd-8c60-0b5b-9ae2850c6774
📄 ObservationDefinition/2c5683d6-6e94-825b-056a-129a04c95e2f
📄 ObservationDefinition/186eb33e-a01d-4252-166c-b5ba5e8a697c
📄 ObservationDefinition/b62b9524-53af-84ae-1071-2867a2169851
📄 ObservationDefinition/73d9d304-a0b8-31b6-1165-346563b9305e
📄 ObservationDefinition/363384c8-0d79-5ff0-5538-4933f99d6409
📄 ObservationDefinition/ef781c18-8e86-7859-209b-469ee9ad42d8
📄 ObservationDefinition/792ae02e-5ba3-13d1-8cc2-fd24a22f7f0b
📄 ObservationDefinition/58cb0710-0ee6-1b7a-2a64-61a01df95ac2
📄 ObservationDefinition/9bc183ee-6017-789b-8a6f-6a5c339f9ae0
▼ 🧪 Specimen 7 samples
▶ 📦 SpecimenDefinition 2 definitions
📄 SpecimenDefinition/3a0cde98-4a73-6d67-1dfc-08e3fc9646a2
📄 SpecimenDefinition/e95109ac-5ef9-1723-3506-2ef2f2e33d87
▶ 📊 Observation 7 Observations
📄 Observation/6fabbf78-9678-8030-485f-b149956308d5
📄 Observation/74535cc6-5232-5ab5-81cf-167a480795e5
📄 Observation/8bf75da1-9221-66fe-6725-c64cb45a57e6
📄 Observation/e803ad6d-0cb3-87dd-6af1-4b88c654a47c
📄 Observation/3519f84a-2889-90a0-a6b7-ff2f1be66a73
📄 Observation/2ef362f1-0b65-3578-7f06-fbd74a24694a
📄 Observation/72e0640b-094b-909e-5268-3dee92af4bbd
▶ 🏢 Organization 4 resources
📄 Organization/033ce81d-5f0d-7a3e-93d3-fc64e122a1fd
📄 Organization/2dd49242-4bf1-9ec1-5f1e-22ba8d4d5ccc
📄 Organization/e3d2bc19-2f10-2b4d-1741-e4135fe612a9
📄 Organization/49d2f0c0-4b28-9271-8aaf-2996a8b9739c
▶ 💠 Substance 3 resources
📄 Substance/fc078762-81c5-5656-9744-13c7ad1e595b
📄 Substance/cb31d747-2338-88d5-342c-8e9c097e4dad
📄 Substance/1551f97b-6f6d-825e-1fb3-44b0b090808c
▼ 🧪 Specimen 7 samples
▶ 📦 SpecimenDefinition 2 definitions
SpecimenDefinition/3a0cde98-4a73-6d67-1dfc-08e3fc9646a2
SpecimenDefinition/e95109ac-5ef9-1723-3506-2ef2f2e33d87
▶ 📊 Observation 7 Observations
Observation/6fabbf78-9678-8030-485f-b149956308d5
Observation/74535cc6-5232-5ab5-81cf-167a480795e5
Observation/8bf75da1-9221-66fe-6725-c64cb45a57e6
Observation/e803ad6d-0cb3-87dd-6af1-4b88c654a47c
Observation/3519f84a-2889-90a0-a6b7-ff2f1be66a73
Observation/2ef362f1-0b65-3578-7f06-fbd74a24694a
Observation/72e0640b-094b-909e-5268-3dee92af4bbd
▶ 🏢 Organization 4 resources
Organization/033ce81d-5f0d-7a3e-93d3-fc64e122a1fd
Organization/2dd49242-4bf1-9ec1-5f1e-22ba8d4d5ccc
Organization/e3d2bc19-2f10-2b4d-1741-e4135fe612a9
Organization/49d2f0c0-4b28-9271-8aaf-2996a8b9739c
▶ 💠 Substance 3 resources
Substance/fc078762-81c5-5656-9744-13c7ad1e595b
Substance/cb31d747-2338-88d5-342c-8e9c097e4dad
Substance/1551f97b-6f6d-825e-1fb3-44b0b090808c
▼ 🧪 Specimen 28 samples
▶ 📦 SpecimenDefinition 2 definitions
▶ 📊 Observation 189 Observations
▶ 🏢 Organization 2 resources

Related Module 3 Documents

3.2.P.1 Description and Composition

Stelbatolol is formulated as an immediate-release, oral, solid dosage form in strengths of 20 mg of the free base equivalent. The 20 mg strength is presented as an orange, round, film coated tablet, debossed with '175' on one side.

Ingredient Role Amount per Tablet % w/w
Stelbatolol Active 15.2 mg 97.9%
Mannitol Excipient 145.0 mg 1.0%
Maize Starch Excipient 13.8 mg 0.5%
Calcium Carboxymethylcellulose Excipient 4.0 mg 0.25%
Magnesium Stearate Excipient 2.0 mg 0.35%

3.2.P.3 Batch Formula

Ingredient Large Batch (722,000 tabs) Small Batch (371,000 tabs)
Stelbatolol 10.98 kg 5.98 kg
Mannitol 104.72 kg 52.36 kg
Maize Starch 9.98 kg 5.99 kg
Calcium Carboxymethylcellulose 2.90 kg 1.45 kg
Magnesium Stearate 1.44 kg 0.72 kg

3.2.P.5.1 Specification

Test Parameter Method Acceptance Criteria
Description Visual inspection An orange film-coated tablet, debossed with 175 on one side
Identification ID by UHPLC Consistent with the retention time and UV spectrum of the reference standard
Assay Assay by UHPLC 95% to 105% of label claim
Dissolution Apparatus 2 (paddles) Shall comply with the requirements of the harmonised USP/JP/Ph Eur Q=80% at 30 minutes
Degradation Products UHPLC Total degradation products ≤ 1.4% w/w
Water Content USP <921> ≤ 1.0% w/w
Microbiological Quality Ph Eur Shall comply with the requirements of the Ph Eur

Resource Detail

Resource Detail